Developer docs
API playgroundTry for free, no card

Search company profiles

FABRX ARTIFICIAL INTELLIGENCE SL

Full company profile

uuid0023ztj

Namestring
FABRX ARTIFICIAL INTELLIGENCE SL
Legal namestring
FABRX ARTIFICIAL INTELLIGENCE S.L.U.
Websiteurl
fabrx-ai.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

FABRX Artificial Intelligence S.L.U. is a Spanish start-up, headquartered in Santiago de Compostela, that operates as a 2023 spin-off from UK-based FABRX Ltd to commercialize AI-powered software for pharmaceutical 3D printing. The company sells three integrated products: M3DIMAKER STUDIO, a full pipeline for modeling, slicing, printer control and AI-based quality validation on FABRX's M3DIMAKER hardware; M3DISEEN, an AI-driven prediction engine that forecasts 3D printability, starting printing parameters and dissolution profiles of drug-excipient formulations; and M3DIFEEDBACK, a customizable phone and web application for collecting patient and caregiver feedback during clinical trials, deployable on FABRX AI cloud or customer infrastructure.

Underlying technology focuses on domain-specialized predictive models trained on pharmaceutical formulation data (particularly hot melt extrusion / FDM filaments), combined with inline sensor data (near-infrared, balance, pressure, bubble detection) for real-time quality assurance. The product suite is designed to bridge formulation development, manufacturing, and patient-side data capture within a single regulated workflow for personalized medicine.

Revenue mechanics are multi-streamed: M3DISEEN operates as a freemium academic web tool (free for research, with future commercial tiers implied); M3DIMAKER STUDIO is offered as restricted-use licensed software for healthcare with quote-based annual pricing; and M3DIFEEDBACK is delivered as custom development per clinical project. Go-to-market is enterprise field sales targeting five named segments — universities, hospitals, pharmacies, CDMOs and pharmaceutical companies — via consultation requests and conference participation. The sole disclosed funding is a 2025 CDTI INTELLIDOSE project grant of €43,145 cofinanced by NextGenerationEU and the Galicia regional government.

Short descriptiontext

FABRX AI is a Spanish spin-off that builds AI-powered software for pharmaceutical 3D printing, including printability prediction, printer control with inline quality validation, and patient feedback collection for personalized-medicine manufacturers, hospitals, pharmacies, CDMOs and academic researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical 3D printing software, AI formulation prediction, personalized medicine manufacturing, clinical trial feedback apps, printability prediction tools
Industry2 codes
PRIMARYIMAAACAD
Machine Control, Firmware & Print Management
Industrials, Manufacturing & Construction/3D Printing/3D Printing Software (CAD/CAM, Slicing, Simulation, Workflow)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Industrial Instruments For Measurement, Display, And Control3823
Product category
Pharmaceutical 3D Printing Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1M3DISEEN (Academic)
TypeFreemium
Description

M3DISEEN is currently available for free as an academic project, suggesting a freemium model where the free version targets academic/research users with potential for commercial licensing in the future.

fabrx-ai.com
2M3DIMAKER STUDIO Software Licensing
TypeSubscription Recurring
Description

M3DIMAKER STUDIO is described as software that can be freely used for research and development or restricted for controlled use in healthcare, suggesting a licensing model with different tiers for research vs. commercial/healthcare applications.

fabrx-ai.com
3Custom Application Development
TypeProfessional Services
Description

The company offers custom downloadable apps for each clinical project through M3DIFEEDBACK, suggesting professional services or custom development revenue from healthcare institutions and clinical projects.

fabrx-ai.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details2 tiers
1M3DISEEN - Academic Free Tier
ModelFreemiumBilling cadenceOthers
Notes

Currently available online for free for academic/research purposes. Plans to include additional 3D printing technologies in the future.

fabrx-ai.com
2Enterprise/Healthcare Licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for commercial healthcare applications and controlled use in clinical settings.

fabrx-ai.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1M3DIMAKER STUDIO
Description

Complete software solution for 3D printing of medicines including features to simplify the printing process and validate printing using AI techniques. Controls M3DIMAKER printers and quality control upgrades.

fabrx-ai.com
+2 more records
Core offering1 text field

FABRX AI develops and sells AI-powered software for pharmaceutical 3D printing of personalised medicines. Its product suite includes M3DIMAKER STUDIO for printer control and quality validation, M3DISEEN for AI-based prediction of formulation printability and dissolution, and M3DIFEEDBACK for collecting patient and caregiver feedback in clinical studies. The software is tightly integrated with FABRX Ltd's M3DIMAKER 3D printers and serves hospitals, pharmacies, CDMOs, and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces formulation development costs by predicting 3D printability before physical testing
+2 more records
Product overview1 text field

FABRX AI offers a suite of three integrated software products for pharmaceutical 3D printing: M3DIMAKER STUDIO provides complete printer control and quality assurance; M3DISEEN delivers AI-powered printability prediction; and M3DIFEEDBACK enables patient feedback collection for clinical studies. These products work together to enable personalized medicine manufacturing through 3D printing technology, from formulation development through patient care.

Product and service3 records
1M3DIMAKER STUDIO
CategoryPharmaceutical 3D Printing Software
Description

Complete software solution for 3D printing of medicines that enables 3D modeling, slicing, and printer control of M3DIMAKER pharmaceutical 3D printers. Includes inline quality-control upgrades such as in-built balance and near-infrared sensor integration, real-time pressure and bubble-formation monitoring via the SSE Laguna printhead, and a GCode library generator for validated, controlled-use printing in healthcare.

2M3DISEEN
CategoryAI Formulation Prediction
Description

AI-driven prediction tool that forecasts 3D printability of pharmaceutical formulations. By inputting drug choice, excipients, and proportions, the tool predicts printability, suggested printing parameters, and dissolution characteristics. Uses large-scale data-driven models to predict physical properties of filaments manufactured by hot melt extrusion. Currently available online for free for academic research and limited to FDM technology.

3M3DIFEEDBACK
CategoryClinical Trial Feedback Software
Description

Customisable phone application and web application system for collecting patient and parent/caregiver feedback in clinical trials. Includes patient management with code-based identification for privacy, feedback export to CSV, user account management with access restrictions, and cloud deployment options on FABRX AI cloud or customer cloud infrastructure. FABRX AI offers custom downloadable apps per clinical project.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

FABRX AI is a spin-off company from FABRX Ltd, a UK-based company specializing in 3D printing of medicines. FABRX Ltd provides the hardware platform (M3DIMAKER 3D printers) that FABRX AI's software products (M3DIMAKER STUDIO) are designed to control and integrate with. This is a core strategic relationship as FABRX AI leverages FABRX Ltd's pharmaceutical 3D printing expertise and hardware for its software solutions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Stratasys is a global leader in polymer 3D printing systems with solutions across healthcare, aerospace, and automotive. It is a broad incumbent providing 3D printing hardware, materials, and software stacks in overlapping verticals.

TypeEmerging player
Description

Schrödinger provides AI-driven computational chemistry and predictive modeling platforms for drug discovery and materials science. It is an emerging player with overlapping AI for pharmaceutical experimentation and formulation prediction.

TypeBroad incumbent
Description

3D Systems is a large, established additive manufacturing company with healthcare-focused 3D printing solutions including surgical planning, dental, and personalized medical devices. It is a broad incumbent in medical and pharmaceutical 3D printing.

TypeBroad incumbent
Description

Materialise is an established 3D printing software and services provider with a broad portfolio spanning medical, industrial, and consumer applications. It is comparable as a broader incumbent in 3D printing software workflows.

TypeDirect peer
Description

FABRX Ltd is the UK-based parent company of FABRX AI and produces the M3DIMAKER pharmaceutical 3D printers that FABRX AI's software (M3DIMAKER STUDIO) is designed to control. They operate in the same pharmaceutical 3D printing space from complementary hardware and software angles.

TypeEmerging player
Description

BenchSci applies AI to biomedical research and experimental reagent selection. It is an emerging player in AI for pharmaceutical experimentation that intersects with FABRX AI's experiment-optimization thesis.

TypeBroad incumbent
Description

Cytiva (formerly part of GE Healthcare Life Sciences) supplies bioprocessing and pharmaceutical manufacturing tools. It is a broad incumbent serving pharma manufacturing customers that FABRX AI also targets.

TypeDirect peer
Description

Aprecia is the maker of Spritam (the first FDA-approved 3D printed drug) and develops ZipDose 3D printing technology for pharmaceutical manufacturing. It is a direct peer in commercial pharmaceutical 3D printed drug development and production.

TypeBroad incumbent
Description

Merck's Life Science division supplies pharma manufacturing and formulation tools, excipients, and laboratory products. It is a broad incumbent serving the pharmaceutical formulation and manufacturing customers FABRX AI addresses.

TypeDirect peer
Description

Triastek is a China-based pharmaceutical company focused on 3D printing of medicines using proprietary Melt Extrusion Deposition (MED) technology. It is a direct competitor in pharmaceutical 3D printing formulation and manufacturing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FABRX ARTIFICIAL INTELLIGENCE SL

Pharmaceutical 3D Printing Softwarefabrx-ai.com

FABRX AI is a Spanish spin-off that builds AI-powered software for pharmaceutical 3D printing, including printability prediction, printer control with inline quality validation, and patient feedback collection for personalized-medicine manufacturers, hospitals, pharmacies, CDMOs and academic researchers.

What FABRX ARTIFICIAL INTELLIGENCE SL does

FABRX Artificial Intelligence S.L.U. is a Spanish start-up, headquartered in Santiago de Compostela, that operates as a 2023 spin-off from UK-based FABRX Ltd to commercialize AI-powered software for pharmaceutical 3D printing. The company sells three integrated products: M3DIMAKER STUDIO, a full pipeline for modeling, slicing, printer control and AI-based quality validation on FABRX's M3DIMAKER hardware; M3DISEEN, an AI-driven prediction engine that forecasts 3D printability, starting printing parameters and dissolution profiles of drug-excipient formulations; and M3DIFEEDBACK, a customizable phone and web application for collecting patient and caregiver feedback during clinical trials, deployable on FABRX AI cloud or customer infrastructure.

Underlying technology focuses on domain-specialized predictive models trained on pharmaceutical formulation data (particularly hot melt extrusion / FDM filaments), combined with inline sensor data (near-infrared, balance, pressure, bubble detection) for real-time quality assurance. The product suite is designed to bridge formulation development, manufacturing, and patient-side data capture within a single regulated workflow for personalized medicine.

Revenue mechanics are multi-streamed: M3DISEEN operates as a freemium academic web tool (free for research, with future commercial tiers implied); M3DIMAKER STUDIO is offered as restricted-use licensed software for healthcare with quote-based annual pricing; and M3DIFEEDBACK is delivered as custom development per clinical project. Go-to-market is enterprise field sales targeting five named segments — universities, hospitals, pharmacies, CDMOs and pharmaceutical companies — via consultation requests and conference participation. The sole disclosed funding is a 2025 CDTI INTELLIDOSE project grant of €43,145 cofinanced by NextGenerationEU and the Galicia regional government.

FABRX ARTIFICIAL INTELLIGENCE SL firmographics

Firmographics
Name
FABRX ARTIFICIAL INTELLIGENCE SL
Legal name
FABRX ARTIFICIAL INTELLIGENCE S.L.U.
Website
https://fabrx-ai.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
FABRX AI is a Spanish spin-off that builds AI-powered software for pharmaceutical 3D printing, including printability prediction, printer control with inline quality validation, and patient feedback collection for personalized-medicine manufacturers, hospitals, pharmacies, CDMOs and academic researchers.
Ownership category
akta.pro rank

FABRX ARTIFICIAL INTELLIGENCE SL industry classification

Industry
Product category
Pharmaceutical 3D Printing Software
NAICS
Software Publishers (513210)
SIC
Industrial Instruments For Measurement, Display, And Control (3823)
akta.pro industry
PRIMARYIMAAACAD
Machine Control, Firmware & Print Management
Industrials, Manufacturing & Construction/3D Printing/3D Printing Software (CAD/CAM, Slicing, Simulation, Workflow)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Pharmaceutical 3D printing software
  • AI formulation prediction
  • Personalized medicine manufacturing
  • Clinical trial feedback apps
  • Printability prediction tools

Where FABRX ARTIFICIAL INTELLIGENCE SL is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

FABRX ARTIFICIAL INTELLIGENCE SL business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. M3DISEEN (Academic): M3DISEEN is currently available for free as an academic project, suggesting a freemium model where the free version targets academic/research users with potential for commercial licensing in the future.
  2. M3DIMAKER STUDIO Software Licensing: M3DIMAKER STUDIO is described as software that can be freely used for research and development or restricted for controlled use in healthcare, suggesting a licensing model with different tiers for research vs. commercial/healthcare applications.
  3. Custom Application Development: The company offers custom downloadable apps for each clinical project through M3DIFEEDBACK, suggesting professional services or custom development revenue from healthcare institutions and clinical projects.

Pricing tiers

ModelBillingPrice
FreemiumOthersM3DISEEN - Academic Free Tier
SubscriptionAnnualEnterprise/Healthcare Licensing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

FABRX ARTIFICIAL INTELLIGENCE SL product offering

Product offering

Core offering

FABRX AI develops and sells AI-powered software for pharmaceutical 3D printing of personalised medicines. Its product suite includes M3DIMAKER STUDIO for printer control and quality validation, M3DISEEN for AI-based prediction of formulation printability and dissolution, and M3DIFEEDBACK for collecting patient and caregiver feedback in clinical studies. The software is tightly integrated with FABRX Ltd's M3DIMAKER 3D printers and serves hospitals, pharmacies, CDMOs, and pharmaceutical companies.

Product overview

FABRX AI offers a suite of three integrated software products for pharmaceutical 3D printing: M3DIMAKER STUDIO provides complete printer control and quality assurance; M3DISEEN delivers AI-powered printability prediction; and M3DIFEEDBACK enables patient feedback collection for clinical studies. These products work together to enable personalized medicine manufacturing through 3D printing technology, from formulation development through patient care.

Differentiator

Problem solved

Functional benefit

Brands

  • M3DIMAKER STUDIO: Complete software solution for 3D printing of medicines including features to simplify the printing process and validate printing using AI techniques. Controls M3DIMAKER printers and quality control upgrades.
  • M3DISEEN
  • M3DIFEEDBACK

Products and services

  • M3DIMAKER STUDIO Complete software solution for 3D printing of medicines that enables 3D modeling, slicing, and printer control of M3DIMAKER pharmaceutical 3D printers. Includes inline quality-control upgrades such as in-built balance and near-infrared sensor integration, real-time pressure and bubble-formation monitoring via the SSE Laguna printhead, and a GCode library generator for validated, controlled-use printing in healthcare.
  • M3DISEEN AI-driven prediction tool that forecasts 3D printability of pharmaceutical formulations. By inputting drug choice, excipients, and proportions, the tool predicts printability, suggested printing parameters, and dissolution characteristics. Uses large-scale data-driven models to predict physical properties of filaments manufactured by hot melt extrusion. Currently available online for free for academic research and limited to FDM technology.
  • M3DIFEEDBACK Customisable phone application and web application system for collecting patient and parent/caregiver feedback in clinical trials. Includes patient management with code-based identification for privacy, feedback export to CSV, user account management with access restrictions, and cloud deployment options on FABRX AI cloud or customer cloud infrastructure. FABRX AI offers custom downloadable apps per clinical project.

Quantifiable outcome

  • Reduces formulation development costs by predicting 3D printability before physical testing
  • +2 more outcomes

Companies that use FABRX ARTIFICIAL INTELLIGENCE SL

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

FABRX ARTIFICIAL INTELLIGENCE SL technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

FABRX ARTIFICIAL INTELLIGENCE SL partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • FABRX LtdcoreStrategic or Co-development PartnerFABRX AI is a spin-off company from FABRX Ltd, a UK-based company specializing in 3D printing of medicines. FABRX Ltd provides the hardware platform (M3DIMAKER 3D printers) that FABRX AI's software products (M3DIMAKER STUDIO) are designed to control and integrate with. This is a core strategic relationship as FABRX AI leverages FABRX Ltd's pharmaceutical 3D printing expertise and hardware for its software solutions.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

FABRX ARTIFICIAL INTELLIGENCE SL competitors and assessment

Company assessment

Broad incumbents

  • Stratasys: Stratasys is a global leader in polymer 3D printing systems with solutions across healthcare, aerospace, and automotive. It is a broad incumbent providing 3D printing hardware, materials, and software stacks in overlapping verticals.
  • 3D Systems: 3D Systems is a large, established additive manufacturing company with healthcare-focused 3D printing solutions including surgical planning, dental, and personalized medical devices. It is a broad incumbent in medical and pharmaceutical 3D printing.
  • Materialise: Materialise is an established 3D printing software and services provider with a broad portfolio spanning medical, industrial, and consumer applications. It is comparable as a broader incumbent in 3D printing software workflows.
  • Cytiva: Cytiva (formerly part of GE Healthcare Life Sciences) supplies bioprocessing and pharmaceutical manufacturing tools. It is a broad incumbent serving pharma manufacturing customers that FABRX AI also targets.
  • Merck Life Science: Merck's Life Science division supplies pharma manufacturing and formulation tools, excipients, and laboratory products. It is a broad incumbent serving the pharmaceutical formulation and manufacturing customers FABRX AI addresses.

Emerging players

  • Schrödinger: Schrödinger provides AI-driven computational chemistry and predictive modeling platforms for drug discovery and materials science. It is an emerging player with overlapping AI for pharmaceutical experimentation and formulation prediction.
  • BenchSci: BenchSci applies AI to biomedical research and experimental reagent selection. It is an emerging player in AI for pharmaceutical experimentation that intersects with FABRX AI's experiment-optimization thesis.

Direct peers

  • FABRX Ltd: FABRX Ltd is the UK-based parent company of FABRX AI and produces the M3DIMAKER pharmaceutical 3D printers that FABRX AI's software (M3DIMAKER STUDIO) is designed to control. They operate in the same pharmaceutical 3D printing space from complementary hardware and software angles.
  • Aprecia Pharmaceuticals: Aprecia is the maker of Spritam (the first FDA-approved 3D printed drug) and develops ZipDose 3D printing technology for pharmaceutical manufacturing. It is a direct peer in commercial pharmaceutical 3D printed drug development and production.
  • Triastek: Triastek is a China-based pharmaceutical company focused on 3D printing of medicines using proprietary Melt Extrusion Deposition (MED) technology. It is a direct competitor in pharmaceutical 3D printing formulation and manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

FABRX ARTIFICIAL INTELLIGENCE SL social profiles

Digital presence

FABRX ARTIFICIAL INTELLIGENCE SL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FABRX ARTIFICIAL INTELLIGENCE SL leadership team

Management profile

Number of profiles

FABRX ARTIFICIAL INTELLIGENCE SL funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FABRX ARTIFICIAL INTELLIGENCE SL M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FABRX ARTIFICIAL INTELLIGENCE SL

What does FABRX ARTIFICIAL INTELLIGENCE SL do?

FABRX AI develops and sells AI-powered software for pharmaceutical 3D printing of personalised medicines. Its product suite includes M3DIMAKER STUDIO for printer control and quality validation, M3DISEEN for AI-based prediction of formulation printability and dissolution, and M3DIFEEDBACK for collecting patient and caregiver feedback in clinical studies. The software is tightly integrated with FABRX Ltd's M3DIMAKER 3D printers and serves hospitals, pharmacies, CDMOs, and pharmaceutical companies.

Is FABRX ARTIFICIAL INTELLIGENCE SL a public or private company?

FABRX ARTIFICIAL INTELLIGENCE SL is a private company. It is classified as corporate owned and is currently operating.

When was FABRX ARTIFICIAL INTELLIGENCE SL founded?

FABRX ARTIFICIAL INTELLIGENCE SL was founded in 2014. It employs 1 to 10 people.

Where is FABRX ARTIFICIAL INTELLIGENCE SL based?

FABRX ARTIFICIAL INTELLIGENCE SL is headquartered in London, United Kingdom, in the Europe region.

How does FABRX ARTIFICIAL INTELLIGENCE SL make money?

Three revenue lines are on record. M3DISEEN (Academic) is the primary driver. The others are M3DIMAKER STUDIO Software Licensing and custom Application Development.

Who are FABRX ARTIFICIAL INTELLIGENCE SL's main competitors?

Broad incumbents on record are Stratasys, 3D Systems, Materialise, Cytiva and Merck Life Science. Emerging players are Schrödinger and BenchSci. Direct peers are FABRX Ltd, Aprecia Pharmaceuticals and Triastek.

Does FABRX ARTIFICIAL INTELLIGENCE SL have an API?

No public API is recorded for FABRX ARTIFICIAL INTELLIGENCE SL.

What industry is FABRX ARTIFICIAL INTELLIGENCE SL in?

FABRX ARTIFICIAL INTELLIGENCE SL's product category is Pharmaceutical 3D Printing Software. Its primary akta.pro industry code is IMAAACAD, Machine Control, Firmware & Print Management, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 513210 and its SIC code is 3823.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales